<DOC>
	<DOCNO>NCT00882947</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy inhale Iloprost ( Ventavis® ) among adult Chinese patient primary pulmonary hypertension , compliance Chinese SFDA regulation .</brief_summary>
	<brief_title>Post-Marketing Surveillance Ventavis® Chinese Patients With Primary Pulmonary Hypertension ( PPH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Both male female age 1865 year old The treating physician chosen Ventavis suitable longterm treatment patient Patient Primary Pulmonary Hypertension ( i.e . IPAH FPAH ) classify NYHA functional class III Written informed/data protection consent No prior treatment Ventavis active treatment PPH within 6 week date study . Known newly identify contraindication administration Ventavis state Ventavis product package insert .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Primary Pulmonary Hypertension ( PPH )</keyword>
</DOC>